enGene Therapeutics

ENGN · NASDAQ

$1.67+$0.09 (+5.70%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $1.58

ENGN analyst rating

HoldConsensus of 11 analysts over the last 12 months. 45% rate it a buy.

Strong buy0
Buy5
Hold5
Underperform1
Sell0

12-month price target · 12 analysts

Average $7.80 (+367.2% upside)

Low: $2.02
Now: $1.67
High: $28.35

Upgrades and downgrades

The latest rating actions, newest first

ENGN analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Citizens	Sep 9, 2026	Maintains	Market Perform	—	14%
HC Wainwright & Co.	Sep 8, 2026	Maintains	Buy	$4.00	41%
Morgan Stanley	Jun 18, 2026	Downgrade	Equal-Weight → Underweight	—	57%
HC Wainwright & Co.	Jun 16, 2026	Maintains	Buy	$6.00 → $4.00	41%
UBS	May 14, 2026	Maintains	Neutral	$9.00 → $2.00	41%
Citizens	May 8, 2026	Downgrade	Market Outperform → Market Perform	—	14%
Guggenheim	May 8, 2026	Downgrade	Buy → Neutral	—	62%
Wells Fargo	May 8, 2026	Downgrade	Overweight → Equal-Weight	$25.00 → $2.00	32%
HC Wainwright & Co.	May 8, 2026	Maintains	Buy	$25.00 → $6.00	41%
Piper Sandler	May 8, 2026	Downgrade	Overweight → Neutral	$7.00 → $4.00	55%

The case for and against

Updated Oct 14, 2026

Bull case

enGene Therapeutics is attractive because detalimogene combines an accelerated approval path with a practical, non-viral delivery profile that addresses the ease-of-use, tolerability, and administration burden that matter in community NMIBC care. Management’s confidence is reinforced by payer feedback suggesting coverage if the therapy is included in NCCN guidelines with 2A, while the KOL event highlighted workflow and economic constraints that could favor its short dwell time and simple workflow. Although the pivotal dataset is still immature, AUA 2026 showed a 54% CR anytime rate and 25% 12-month CR, and the surfactant cohort plus planned 4Q26 readout could strengthen durability and support BLA progress.

Bear case

enGene Therapeutics is viewed negatively because its lead program remains exposed to substantial clinical risk, with prior LEGEND data falling below expectations on efficacy and durability and raising uncertainty about the consistency of its mechanism of action. The company also faces meaningful regulatory, commercial, and competitive hurdles, while its development-stage business still burns cash, posting a $32.5M net loss in 3Q26 and a $30.2M net loss in 1Q26, even as cash, cash equivalents, and marketable securities declined from $285.5M to $266.3M. Although a 4Q26 pre-BLA meeting and updated pivotal cohort data could de-risk the story, the need for additional equity financing to complete development adds dilution risk and limits confidence in the investment case.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.